Simultaneously, the company is gearing up for a multi-country commercialization of semaglutide, a high-demand GLP-1 drug, which is expected to unlock significant global opportunities as patents expire starting in 2026 [cite: Source A]
Haroon E, Daguanno AW, Woolwine BJ, Goldsmith DR, Baer WM, Wommack EC, et al
But it leaves the question of why they occur in the first place
[DOI] [Google Scholar] 28.Harington C.R., Mead T.H
Wegovy FDA highlights of prescribing information, Food and Drug Administration (2024) Kaiser Permanente Northwest Region criteria for drug coverage: Semaglutide (Wegovy), Kaiser Permanente (2025) Check your cost and coverage, Wegovy (2025) Medicare plans to start covering weight-loss drugs, National Association of Manufacturers (2024) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Established HGH adverse effects: Licensed somatropin SmPCs document a range of recognised adverse effects, including arthralgia, myalgia, peripheral oedema, carpal tunnel syndrome, paraesthesia, and headache
